Ekachai Medical Care PCL

Ekachai Medical Care maintains a strong liquidity position with a current ratio of 4.0, indicating the company can cover its short-term obligations four times over. However, the firm's free cash flow is negative at -257.5 million THB, and capital expenditures are substantial at -391.0 million THB, suggesting ongoing investment in infrastructure or expansion. The company's price-to-book ratio of 1.67 and price-to-tangible-book ratio of 1.67 suggest a moderate premium to its book value, while the price-to-earnings ratio of 15.13 is in line with typical valuations for healthcare services firms. Profitability metrics show a return on equity of 11.06% and a return on assets of 8.91%, both of which are strong relative to the healthcare industry. The company's operating income of 315.3 million THB and net income of 262.3 million THB reflect solid operational performance. Gross profit of 517.7 million THB on revenue of 1.24 billion THB indicates a gross margin of approximately 41.8%, which is consistent with the industry's typical profitability. The company's revenue is concentrated in Thailand, with no disclosed international operations. Its services span a broad range of medical centers, including pediatrics, obstetrics, general surgery, and health promotion, which helps diversify its revenue streams. However, the lack of geographic diversification could expose the company to local economic or regulatory risks. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The mean price target of 4.90 THB from analysts is nearly aligned with the current market price of 4.96 THB, suggesting limited upside potential in the near term. The company's capital expenditures and free cash flow suggest a focus on maintaining and expanding its existing facilities rather than aggressive growth. The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. While the debt-to-equity ratio is low at 0.03, the firm's long-term debt of 77.2 million THB could become a concern if interest rates rise or if the company faces unexpected cash flow constraints. The dilution risk is assessed as low, with no near-term pressure from share issuance or dilutive events. Recent filings and transcripts do not indicate any material changes in the company's operations or strategy. The firm continues to focus on its core hospital and infertility services, with no significant new product launches or market expansions disclosed in the latest reports.